bjgabrielsen

Darolutamide Delays the Spread of Prostate Cancer in Men with Non-Metastatic, Hormone-Resistant Disease.

Results from a Phase 3 clinical trial reveal that adding the androgen receptor inhibitor darolutamide to androgen deprivation (hormone) therapy (ADT) extends by 22 months the time men with hormone-resistant prostate cancer live without metastasis and without increasing the incidence of adverse events. The treatment also extended survival, time to pain progression, time until chemotherapy was needed, and kept patients more »

Can God Use Cancer?

I recently received an e mail from the Cancer Treatment Centers of America (CTCA) entitled Health, Hope and Inspiration. These periodic e mails contain 30 minute interviews with Rev. Percy McCray, spiritual coordinator for CTCA. The latest interview entitled “Can God Use Cancer?” grabbed my attention. Rev. McCray’s immediate answer to the question was a more »

Simple Blood Tests to Determine Best Treatment Options for Advanced Prostate Cancer

Blood tests that examine circulating tumor cells, CTC’s, (cells that shed from the tumor or metastasis into circulation), for the presence of a mutated AR-V7  protein, could help determine if a patient with advanced prostate cancer would fare better with chemotherapy or with medicines such as enzalutamide (Xtandi) or abiraterone (Zytiga) that target the androgen receptor (a cellular more »

Managing Cancer Pain; Are Better Approaches on the Horizon?

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) publishes an e mail blog entitited Current Contents to which one can subscribe. On January 23rd, their blog focused on non-opiod methods of managing cancer pain (see below).  Pain is a common and much-feared symptom among people being treated for cancer and long-term more »

Excellent Informative Prostate Cancer Videos on Several Subjects

The Prostate Cancer Research Institute (PCRI) has produced several short videos covering many aspects of the disease including, imunotherapy, brachytherapy, intensity-modulated radiation therapy (IMRT), sexual disfunction, testosterone levels, and more. The speakers include Dr. Mark Moyad, Dr. Eugene Kwon from the Mayo Clinic and others. It is my understanding that such videos will become available more »

Mind Boggling New Year Promises

“If you want to feel small, just imagine moving at 34 thousand miles per hour for forty years and getting—astronomically speaking—nowhere. Late last year, the Voyager 2 space probe became the second craft to ever leave our solar system. Now 11 billion miles from earth, it is one of the farthest-flung man-made objects in existence. more »

Christmas 2018 and Prostate Cancer

I’ll bet you have never seen the words “Christmas” and “prostate cancer” linked before. Let me start by addressing some personal thoughts about Christmas. When Jesus was born, an angel of the Lord appeared to Joseph, the father of Jesus, and explicitly told him to name the baby “Immanuel” which means “God with us” (Matthew more »

Rubraca (Rucaparib) Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations.

Rubraca (rucaparib), Clovis Oncology‘s oral PARP inhibitor, shrank tumors in 44% of metastatic hormone-resistant prostate cancer (mCRPC) patients with BRCA mutations included in the Phase 2 TRITON2 clinical trial. The treatment, which is already approved for ovarian cancer, also reduced PSA levels — a biomarker of prostate cancer — in 51.1% of patients with BRCA more »

Some Advanced Prostate Cancer Patients May Respond Well to Keytruda Immunotherapy.

Immunotherapy with Keytruda (pembrolizumab) may be an effective way to treat some cases of advanced prostate cancer according to a preliminary study conducted at Oregon Health and Science University – Knight Cancer Institute. Findings were published in the journal Oncotarget in a paper entitled “Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.” Keytruda is a more »